Oslo University Hospital HF
- Address
- lock Available on a paid plan
Digestive System Diseases
The oncology department at Oslo University Hospital HF is conducting trials focused on cancers of the digestive tract, aiming to evaluate new targeted and immunotherapies to improve patient outcomes.
- Evaluation of novel agents in biliary adenocarcinoma
- Study of combination regimens for neuroendocrine tumors of the gastrointestinal system
- Assessment of targeted therapy in gastrointestinal stromal tumors
- Investigation of immunotherapy for MSI‑high advanced solid tumors
Across nine active studies with twelve investigators, the site seeks to extend survival and quality of life for patients with these digestive system malignancies.
Hemic and Lymphatic Diseases
Trials at this hospital explore blood‑related cancers, testing antibody‑drug conjugates and cellular approaches to raise response rates and durability of remission.
- Phase II study of zilovertamab vedotin in relapsed diffuse large B‑cell lymphoma
- Evaluation of subcutaneous mosunetuzumab for early‑relapse follicular lymphoma
- Investigation of novel regimens for lymphoma patients with prior therapy failure
- Biomarker‑driven trials assessing PD‑L1 and MSI status in hematologic malignancies
The program involves multidisciplinary collaboration, aiming to bring effective, less toxic options to individuals facing refractory hematologic cancers.
Neoplasms
The department’s neoplasm portfolio spans solid tumors such as melanoma, lung, and thyroid cancers, with studies testing checkpoint inhibitors and innovative combination strategies.
- Randomized study of nivolumab versus placebo to prevent recurrence in resected stage IIB/C melanoma
- Assessment of pembrolizumab across multiple advanced solid tumors including small cell lung carcinoma
- Combination of LTX‑315 with pembrolizumab for refractory melanoma
- Targeted therapy evaluation in thyroid carcinoma and mesothelioma
With nine clinical trials underway, the site strives to expand therapeutic options and improve long‑term survival for patients with these diverse neoplasms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Region Skane2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Skane2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oslo University Hospital HF
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 2 | Unknown | 2016-02-02 | 2022-10-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.